Blueprint Medicines Corporation

This study is observing how well the drug avapritinib works for people with indolent systemic mastocytosis (ISM) whose symptoms aren't controlled by standard treatments. It will follow about 80 patients in Germany for up to two years as they take the drug as part of their normal …

This study is testing an experimental drug called BLU-808 for people with chronic hives that aren't well-controlled by standard allergy medicines. It aims to see if the drug is safe and if it can reduce symptoms for people whose hives are triggered by things like cold or pressure…

This study is testing whether an investigational drug called BLU-263 can better control symptoms in people with indolent systemic mastocytosis whose current treatments aren't working well enough. Researchers will compare BLU-263 plus standard symptom treatments against placebo pl…

This study continues monitoring the safety of avapritinib for people with systemic mastocytosis who previously participated in related trials and are still benefiting from the medication. It tracks side effects and safety issues over a longer period. The goal is to better underst…

This early-stage study aims to understand how a new drug called elenestinib might change how the body processes two common medications: a sedative (midazolam) and a birth control pill. Researchers will give these medications to 20 healthy adult women, both with and without elenes…

This study aims to find out how often a specific genetic change (the KIT D816V mutation) is present in people who have symptoms that suggest a type of mast cell disease. Researchers will enroll about 450 participants who have unexplained severe allergic reactions, certain chronic…